Dollar rises while global stock index falls; inflation and tariffs in focus
Trump gave Mexico a 90-day reprieve from higher tariffs to negotiate a broader trade deal but was expected to issue higher final duty rates for most other countries as the clock wound down on the Friday deadline.
Earlier in the day, an economic data release showed U.S. inflation increased in June as tariffs on imports started raising the cost of some goods, supporting economists' expectations that price pressures would pick up in the second half of the year.
Thursday's data also showed fewer-than-expected Americans applied for unemployment benefits, while second-quarter U.S. labor costs increased slightly more than expected on a pick-up in wage growth.
The Federal Reserve kept rates steady on Wednesday, and Chair Jerome Powell said the central bank needed to wait for more data before deciding whether to adjust rates in September, sending equities lower on the day and drawing further criticism from Trump.
Indexes saw some support earlier on Thursday from better-than-expected results from Microsoft (MSFT.O), opens new tab and Meta Platforms (META.O), opens new tab but by the end of the day, gains had evaporated.
With the economic data appearing to support the Fed's more hawkish stance and an anxious wait for Friday's payroll report along with Trump's tariff deadline, investors had an awful lot to handle this week, said Kevin Gordon, senior investment strategist at Schwab.
"This is one of those weeks where it's almost too much information to digest, so the market is ignoring it all and staying in a tight range," Gordon said.
However, he noted megacap strength was countering weakness elsewhere in the market including in small-cap companies, which have less latitude to cope with higher prices.
"You really only have communications services and parts of technology that are holding you up today. Breadth is generally pretty weak," the strategist said.
The Russell 2000 (.RUT), opens new tab small cap index ended down 0.93% while the S&P 600 small cap index (.SPCY), opens new tab fell 1.17%.
On Wall Street, the Dow Jones Industrial Average (.DJI), opens new tab fell 330.30 points, or 0.74%, to 44,130.98 and the S&P 500 (.SPX), opens new tab was down 23.51 points, or 0.37%, to 6,339.39 with only two of its 11 major industry sectors showing gains for the day.
The Nasdaq Composite (.IXIC), opens new tab fell 7.23 points, or 0.03%, to 21,122.45.
For the month, the S&P 500 gained 2.17% and the Nasdaq rose 3.7%, while the Dow added 0.08%.
MSCI's gauge of stocks across the globe (.MIWD00000PUS), opens new tab fell 5.31 points, or 0.57%, to 929.02.
Earlier, the pan-European STOXX 600 (.STOXX), opens new tab index finished down 0.75%, at a more than one-week low. European investors were disappointed by corporate earnings reports from the likes of Sanofi and Ferrari, while beverage makers slid as they were a 15% U.S. tariff.
In currencies, the U.S. dollar was eyeing its first monthly gain for 2025 against major currencies, underpinned by hopes for clarity on trade policy and U.S. economic resilience.
For the day, the dollar index , which measures the greenback against a basket of currencies including the yen and the euro, rose 0.26% to 100.05.
The euro was up 0.08% at $1.1413 and the Mexican peso strengthened 0.23% versus the dollar at 18.854.
But against the Japanese yen , the dollar strengthened 0.84% to 150.76 after the Bank of Japan held interest rates steady and increased its inflation forecast.
The Korean won weakened 0.21% against the dollar after Trump's announcement that the U.S. would charge a 15% tariff on imports from South Korea, which would in return invest $350 billion in U.S. projects and purchase $100 billion in U.S. energy products.
In U.S. Treasuries, longer-dated yields were lower before the anticipated July jobs report, reversing an increase on Wednesday following Powell's comment.
The yield on benchmark U.S. 10-year notes fell 0.6 basis points to 4.372%, from 4.378% late on Wednesday, while the 30-year bond yield fell 1.5 basis points to 4.8979%.
But the 2-year note yield, which typically moves in step with interest rate expectations for the Federal Reserve, rose 2 basis points to 3.957%, from 3.937% late on Wednesday.
In oil markets, prices fell 1% after rising in each of the prior three sessions as investors considered the extension of an existing trade deal between the U.S. and Mexico and a surprise build in U.S. crude stocks put pressure on prices.
U.S. crude settled down 1.06%, or 74 cents at $69.26 a barrel while Brent settled at $72.53 per barrel, down 0.97%, or 71 cents on the day.
Gold prices rose as traders turned to the safe-haven asset on tariff uncertainty. Spot gold rose 0.51% to $3,291.55 an ounce.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
25 minutes ago
- Reuters
UK hedge fund Marshall Wace posted mixed returns for July, source says
LONDON, Aug 4 (Reuters) - British hedge fund Marshall Wace returned mixed results in two of its funds in July, a source close to the matter told Reuters on Monday. Co-founded by British financier Paul Marshall, the $76.9 billion firm returned 1.6% in July culminating in a 6.1% performance for 2025 so far in its Eureka Fund, the source said. The hedge fund's Market Neutral Tops fund returned -0.22% for July and is up 10.99% year to date the source added. Systematic stock trading hedge funds, like Marshall Wace, are up roughly 10% for 2025 so far, said Goldman Sachs on Monday.
Telegraph
27 minutes ago
- Telegraph
Bank ‘must cut rates six times' over next year to boost ailing economy
Andrew Bailey must slash interest rates six times over the next year to bolster flagging growth, economists have warned. The Bank of England Governor and his colleagues on the Monetary Policy Committee (MPC) are expected to cut borrowing costs from 4.25pc to 4pc this Thursday. But a growing cohort of economists predict Bank officials will be forced to go much further over the next 12 months. Six cuts would take the base rate to 2.75pc next year – the lowest level since late 2022. Peder Beck-Friis, an economist at Pimco, an investment company, said higher taxes, slower growth and the weakening jobs market will all push the Bank to cut rates further next year. 'While inflation has been surprisingly firm, we see good reasons to expect a slowdown. Regulatory price hikes, including in employment taxes, have pushed prices up, but wage growth is softening and the labour market is weakening,' he said. Companies are passing the £25bn increase in employers' National Insurance contributions on to customers, but 'once this tax shock fades, we expect inflation to ease, as seen in other developed countries'. 'We expect the Bank to accelerate rate cuts later this year, with the policy rate settling near 2.75pc next year,' he said. Michel Nies, from Citi, predicts rate cuts in August and November before an acceleration from December in the wake of 'very likely tax increases in the autumn Budget', taking the base rate to 2.75pc. He cites the weakening jobs market as the critical factor. The economy has lost 178,000 employees on payroll over the past year. Businesses in particular are taking a beating: 'The divergence between public and private sector employment growth continues to widen with the former still masking a sustained contraction in the latter,' Mr Nies said. Bruna Skarica, at Morgan Stanley, also expects cuts to 2.75pc because unemployment has risen to 4.7pc, the highest rate in four years. 'The build-up of slack in the labour market ... can only result in pay and price disinflation over time,' she said. 'The laws of economic gravity can be delayed, but not denied.' These economists remain in the minority, and even this week's anticipated rate cut will not be entirely uncontroversial. Policymakers are cutting interest rates even though inflation, at 3.6pc and rising, is well above its 2pc target. However, monetary policy takes as long as two years to feed through to consumer prices, meaning this week's rate decision will only fully pass through to inflation in mid-2027 - and will have little effect on the rise in living costs this year. Jack Meaning, a former Bank of England economist now at Barclays, forecasts a three-way split on the MPC. He anticipates that two policymakers will vote to hold rates, two for a double cut to 3.75pc, and the majority of five backing a move to 4pc. 'Despite these divergent views on both sides, we think the centre of the committee, and ultimately the decisive bloc, will continue on a gradual and careful quarterly rate cutting path, until it reaches 3.5pc in February 2026,' he said. The most recent three-way split came in May, when external MPC members Swati Dhingra and Alan Taylor voted for a half percentage point rate cut to 4pc.
Reuters
27 minutes ago
- Reuters
Wegovy maker Novo hit with investor class action over revenue forecast cut
Aug 4 (Reuters) - Novo Nordisk ( opens new tab, maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish pharmaceutical giant misled them with optimistic growth forecasts and minimized competition risks in the obesity market. The proposed class action lawsuit, opens new tab was filed on Friday in the federal court in New Jersey following a sharp decline in the company's stock price. Investors knocked $70 billion off Novo Nordisk's market value on a single trading day last week. Novo last week in a statement said it was lowering its 2025 sales and operating profit outlook due to lower growth expectations in the second half in the United States for Wegovy in the obesity market and the drugmaker's Ozempic in the diabetes market. Novo said its updated sales outlook for Wegovy stemmed from the 'persistent' use of compounded versions of the drug, competition and what it described as slower-than-expected market expansion. A representative from Novo and an attorney for the plaintiff did not immediately respond to requests for comment on Monday about the investor lawsuit. The lawsuit was filed on behalf of potentially thousands of investors who purchased Novo's stock between May 7, 2025 and July 28. The tight supply of Wegovy in the United States in 2022 prompted U.S. regulators to temporarily allow the sale of cheaper, compounded versions of the drug, known chemically as semaglutide. The U.S. Food and Drug Administration in February removed Wegovy from the agency's shortage list. Novo in June said it was ending a partnership with telehealth company Hims & Hers that began in late April, citing Hims' alleged improper marketing and sales of Wegovy copies. Novo accused Hims of 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.' Hims CEO Andrew Dudum in a response accused Novo management of misleading the public and making anticompetitive demands. The case is Eric Barta v. Novo Nordisk et al, U.S. District Court, District of New Jersey, No. 2:25-cv-14045. For plaintiff: Adam Apton of Levi & Korsinsky For defendants: No appearances yet Read more: Novo Nordisk shares dip further as Wegovy gains nearly erased Hims & Hers hit with investor lawsuits after Novo ends Wegovy partnership Wegovy maker Novo faces fee demand after losing copycat drug lawsuit Ozempic copies restricted after US judge denies injunction
